Table 1.
Clinical information of studied patients*.
| Chracteristics | Chronic hepatitis B | Liver cirrhosis | Hepatocellular carcinoma | P |
|---|---|---|---|---|
| Patients (n) | 250 | 219 | 143 | |
| Median age (range, y) | 35(12–78) | 49(22–86) | 53.5(31–77) | <0.001 |
| Gender (male/female) | 147/103 | 148/71 | 124/19 | <0.001 |
| HBeAg (+) (%) | 135(54.0) | 48(21.9) | 24(16.8) | |
| (male/female) | 73/62 | 31/17 | 22/2 | 0.002 |
| HBeAg (−) (%) | 79(31.6) | 124(56.6) | 100(69.9) | |
| (male/female) | 49/30 | 85/39 | 87/13 | <0.001 |
| HBV-DNAa (copies/mL in log) | 3.9(1.3–8.6) (176/250)b | 3.45(1.2–7.7) (92/219) | 3.1(1.4–7.9) (64/143) | 0.004 |
| ALTa (U/L) | 27.35(3.2–872) (242/250) | 28.4(4.8–998.5) (214/219) | 32.4(8.7–573.5) (142/143) | 0.371 |
| ASTa (U/L) | 24.8(13.2–707) (242/250) | 32.8(6.3–502.8) (214/219) | 33.95(12.4–285.2) (142/143) | <0.001 |
| AFPa (mg/L) | 2.55(0–365.7) (203/250) | 2.955(0.61–447.8) (208/219) | 6.93(0.61–807.6) (139/143) | <0.001 |
| TBILa (µmol/L) | 11.6(0.9–711) (242/250) | 19(5.9–735.2) (214/219) | 18.95(1.6–397.9) (142/143) | <0.001 |
| DBILa (µmol/L) | 2.2(0.1–87.1) (242/250) | 4.1(0.9–345.2) (214/219) | 4.2(0.8–184.9) (142/143) | <0.001 |
| ALBa (g/L) | 44.5(23.3–52.6) (241/250) | 41(15.4–51.5) (214/219) | 39.9(24.3–52.2) (142/143) | <0.001 |
aindicates the median.
bindicates the number of patients whose clinical data available vs total number of patients throughout the table.
*P value of comparison among groups of CHB, LC and HCC by x2 test/One-Way ANOVA/nonparametric Kruskal Wallis test.